CDKN2A and thyroid cancer: In conclusion, we developed a novel seven-mRNA (CDKN2A, FGF7, CTSB, HAP1, DAPK2, DNAJB1, ITPR1) risk model and nomogram that could help assess the prognosis of patients and guide clinical decision-making and individualized therapy for differentiated thyroid cancer.